Current Status, Position
Dr Ioannis Boukovinas is the Head of Medical Oncology Unit at Bioclinic Thessaloniki. He also is the President of Hellenic Medical Oncology Society.
Dr Ioannis Boukovinas got his pharmaceutical degree in 1980 and Medical degree in 1988 from Aristotle University of Thessaloniki and afterwards, he specialised in internal medicine and medical oncology. He completed his PhD in 2010 from the University of Crete for pharmacogenomics in lung adenocarcinoma.
Dr Ioannis Boukovinas has a special interest in sarcoma, lung cancer, melanoma, rare cancers and GI cancers. He is member of ESMO Sarcoma Faculty since 2008 and member of the Board of Directors of the Hellenic Society of Medical Oncology since 2011. He was elected as President of the Hellenic Society of Medical Oncology for two consecutive periods 2017-2019 and 2019-2021. He contributed in more than 50 articles in peer-reviewed journals and participated in many national and international clinical trials.
Conflict of interest: Dr Boukovinas is the President of the Hellenic Medical Oncology Society. During their congress, the organisation is sponsored and supported by the following companies: Roche, Novartis, Pfizer, MSD, BMS Pfizer, LeoPharma, Sanofi, Astra Zeneca, Astellas Pharma Canada, Inc, Faran, Ipsen, Lilly, Boehringer Ingelheim, Genesis, Demo, Bristol, Servier, Anabiosis, Merck, Janssen, Takeda, Rafarm, Bayer, Angelini, Ariti, Amgen, Innovis, Enorasis, Galenica, Fabre.